SBIR-STTR Award

Sequence selectivity of acridium ester labeled probes
Award last edited on: 3/25/02

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$50,000
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Norman C Nelson

Company Information

Gen Probe Inc (AKA: Gen-Probe Incorporated~Hologic Incorporated)

10210 Genetic Center Drive
San Diego, CA 92121
   (858) 410-8000
   informationservices@gen-probe.com
   www.gen-probe.com
Location: Single
Congr. District: 51
County: San Diego

Phase I

Contract Number: 1R43AI027597-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1989
Phase I Amount
$50,000
The ultimate goal of this project is to develop a DNA probe-based chemiluminescent homogeneous assay system for the rapid, simple, and sensitive detection of infectious disease organisms in clinical samples. The hydrolysis and subsequent loss of chemiluminescence of the acridinium ester attached to a DNA probe has been shown to proceed at a substantially reduced rate when the probe is hybridized to its target nucleic acid as compared to the unhybridized probe. The specific aim of this research is to determine the optimal site of acridinium ester attachment with respect to nucleotide sequence and location within the oligomer to yield a maximum hydrolysis rate differential between hybridized and unhybridized oligomers. These parameters will be studied in a series of defined-sequence oligonucleotides labeled with acridinium ester, using kinetic analysis of the hydrolysis event and determination of thermal stability of the hybrid complex. The data will be used to refine and optimize a chemiluminescent homogeneous assay system based on this differential hydrolysis rate phenomenon. Such an assay system should significantly improve the speed and simplicity with which infectious diseases are currently being diagnosed.

Anticipated Results:
Development of the chemiluminescent homogeneous DNA probe-based assay format for the detection of infectious disease organisms would contribute significantly to the speed and simplicity with which infectious diseases are detected, and as such would be a commercially attractive product.National Institute of Allergy And Infectious Diseases

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----